Axitinib + Ipilimumab in Advanced Melanoma

The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.

Trial Details

NCT ID
NCT04996823
Phase
PHASE2
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Ipilimumab
  • Axitinib
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Diagnosis of advanced/unresectable melanoma - uveal melanoma is excluded
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Adequate bone marrow, organ function and laboratory parameters as defined in protocol.
  • Patients must have adequately controlled blood pressure (\<150 systolic and \<100 diastolic)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →